Abstract: Objective To investigate the expressions of CD133 and Ki67 in patients with giant cell tumor of bone （GCTB） and the relationship with clinicopathological features and prognosis， in order to provide firm evidence for the judgement of biological behavior and the evaluation of prognosis.
MethodsEighty cases of GCTB were analyzed and admitted to our hospital from March 2007 to March 2013. Immunohistochemical method was used to detect the expressions of CD133 and Ki-67 in the cancer tissues of patients with GCTB. The correlations of two proteins with clinicopathological features and prognosis of GCTB patients were analyzed. Results The positive expression of CD133 and Ki-67 in GCTB tissues was 43.8％ （35／80） and 57.5％（46／80）， respectively. The expression of CD133 was related to tumor size， recurrence， Jaffe pathological classification， Campanacci image grade and surgical procedures（P＜0.05）. The expression of Ki-67 was related to tumor size， Jaffe pathological classification and Campanacci image grade（P＜0.05）. The 1， 3， 5year recurrentfree survival rates were 930％， 880％ and 800％. The 1， 3， 5year recurrentfree survival rates of patients with positive and negative CD133 were 89.0％， 83.0％， 75.0％ versus 99.0％， 91.0％，91.0％ respectively， with statistically significant difference（P＜0.05）. The 1， 3， 5year recurrentfree survival rates of patients with positive and negative Ki67 were 89.0％， 75.0％， 68.0％ versus 97.0％， 93.0％， 90.0％ respectively， with statistically significant difference （P＜0.05）.
Conclusion The positive expression of CD133 is closely related to the disease deterioration and recurrence of GCTB. CD133 and Ki67 can serve as the indicator for evaluating malignant degree and prognosis of GCTB.